ImpediMed

ImpediMed DSCR

The Debt Service Coverage Ratio (DSCR) of ImpediMed (IPD.AX) as of Oct 21, 2026 is -1.21. In the previous year, Debt Service Coverage Ratio (DSCR) was -1.01 — a change of 19.43% (lower).

DSCR

-1.21

YoY

19.43%

Last updated:

Debt Service Coverage Ratio (DSCR) of ImpediMed is 2026 -1.21 . Debt Service Coverage Ratio (DSCR) of ImpediMed was 2025 -1.01 . It decreases by 19.43% lower compared to the previous year.

The ImpediMed DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2019
-22.49 AUD
Jan 1, 2020
-22.06 AUD
Jan 1, 2021
-27.97 AUD
Jan 1, 2022
-92.14 AUD
Jan 1, 2023
-12.47 AUD
Jan 1, 2024
-15.56 AUD
Jan 1, 2025
-1.01 AUD
Jan 1, 2026
-1.21 AUD
The ImpediMed DSCR history
YEARDSCRYoY
-1.21+19.43%
-1.01-93.51%
-15.56+24.77%
-12.47-86.46%
-92.14+229.42%
-27.97+26.77%
-22.06-1.89%
-22.49-77.95%
-101.99-76.86%
-440.79+43.51%
-307.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Debt Service Coverage Ratio (DSCR) of ImpediMed is -1.21 in 2026.

Debt Service Coverage Ratio (DSCR) of ImpediMed changed from -1.01 to -1.21, representing a 19.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ImpediMed

All Key Metrics — ImpediMed